CJC-1295
A long-acting GHRH analog studied as a research peptide for sustained growth hormone elevation.
In plain English
CJC-1295 is a synthetic GHRH analog modified to resist enzymatic breakdown. Two versions exist: one with a Drug Affinity Complex (DAC) that binds albumin and extends the half-life to roughly 8 days, and one without DAC (often called Mod GRF 1-29). In a small Phase 1 trial in 2006, CJC-1295 with DAC produced sustained increases in growth hormone and IGF-1 for over a week. Development was paused after a fatal adverse event in a separate Phase 2 program; the originator never brought CJC-1295 to market. Today it is widely used as a research peptide in age-management and recovery clinics. People commonly research CJC-1295 — usually paired with ipamorelin — for body composition, sleep, and recovery.
What it is
CJC-1295 is a tetra-substituted analog of GHRH (1-29). The 'with DAC' variant is conjugated to bind albumin, extending its plasma half-life.
Mechanism (summary)
Like sermorelin, CJC-1295 stimulates pituitary GH release via the GHRH receptor. The DAC modification keeps GHRH activity tonically elevated rather than pulsatile, which is mechanistically different from native physiology.
Why people research it
- Sustained growth hormone elevation
- Body composition in adults with age-related GH decline
- Recovery and sleep quality
- Use in combination with ghrelin-receptor agonists
Human evidence
A 2006 Phase 1 RCT in healthy adults showed CJC-1295 with DAC produced sustained elevations in GH and IGF-1 over multiple days. A Phase 2 program was halted after a fatal adverse event during clinical trials, though causation was disputed. No modern, large, peer-reviewed RCTs exist.
Animal / lab evidence
Animal work supports robust GH and IGF-1 elevation and downstream anabolic effects.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
One shot of CJC-1295 raised growth hormone and IGF-1 for over a week in healthy adults — but the trial was small and short.
In a small trial in older adults, repeated CJC-1295 doses kept GH and IGF-1 elevated.
History
Developed by ConjuChem and later licensed to other companies. Phase 1 results published in 2006. Clinical development was discontinued.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A 29-amino-acid GHRH analog formerly FDA-approved for childhood growth hormone deficiency.
A selective ghrelin receptor agonist studied as a growth hormone secretagogue with minimal effects on cortisol or prolactin.
A long-acting GHRH analog FDA-approved as Egrifta for HIV-associated visceral fat accumulation.